These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 10027883)

  • 1. The pharmacokinetics of ceftazidime during hemodiafiltration in critically ill patients.
    Sato T; Okamoto K; Kitaura M; Kukita I; Kikuta K; Hamaguchi M
    Artif Organs; 1999 Feb; 23(2):143-5. PubMed ID: 10027883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation.
    Mariat C; Venet C; Jehl F; Mwewa S; Lazarevic V; Diconne E; Fonsale N; Carricajo A; Guyomarc'h S; Vermesch R; Aubert G; Bidault R; Bertrand JC; Zeni F
    Crit Care; 2006 Feb; 10(1):R26. PubMed ID: 16507147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of hemopurification rate on doripenem pharmacokinetics in critically ill patients receiving high-flow continuous hemodiafiltration.
    Ohchi Y; Hidaka S; Goto K; Shitomi R; Nishida T; Abe T; Yamamoto S; Yasuda N; Hagiwara S; Noguchi T
    Yakugaku Zasshi; 2011; 131(9):1395-9. PubMed ID: 21881315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered pharmacokinetics of ceftazidime in critically ill patients.
    Gómez CM; Cordingly JJ; Palazzo MG
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1798-802. PubMed ID: 10390248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doripenem pharmacokinetics in critically ill patients receiving continuous hemodiafiltration (CHDF).
    Hidaka S; Goto K; Hagiwara S; Iwasaka H; Noguchi T
    Yakugaku Zasshi; 2010 Jan; 130(1):87-94. PubMed ID: 20046071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients.
    Traunmüller F; Schenk P; Mittermeyer C; Thalhammer-Scherrer R; Ratheiser K; Thalhammer F
    J Antimicrob Chemother; 2002 Jan; 49(1):129-34. PubMed ID: 11751776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of intermittent intraperitoneal ceftazidime.
    Grabe DW; Bailie GR; Eisele G; Frye RF
    Am J Kidney Dis; 1999 Jan; 33(1):111-7. PubMed ID: 9915275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermittent bolus dosing of ceftazidime in critically ill patients.
    Young RJ; Lipman J; Gin T; Gomersall CD; Joynt GM; Oh TE
    J Antimicrob Chemother; 1997 Aug; 40(2):269-73. PubMed ID: 9301994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.
    Stein GE; Smith CL; Scharmen A; Kidd JM; Cooper C; Kuti J; Mitra S; Nicolau DP; Havlichek DH
    Surg Infect (Larchmt); 2019 Jan; 20(1):55-61. PubMed ID: 30351195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermittent and continuous ceftazidime infusion for critically ill trauma patients.
    Hanes SD; Wood GC; Herring V; Croce MA; Fabian TC; Pritchard E; Boucher BA
    Am J Surg; 2000 Jun; 179(6):436-40. PubMed ID: 11004326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age.
    van den Anker JN; Schoemaker RC; Hop WC; van der Heijden BJ; Weber A; Sauer PJ; Neijens HJ; de Groot R
    Clin Pharmacol Ther; 1995 Dec; 58(6):650-9. PubMed ID: 8529330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro AN69 and polysulphone membrane permeability to ceftazidime and in vivo pharmacokinetics during continuous renal replacement therapies.
    Isla A; Gascón AR; Maynar J; Arzuaga A; Sánchez-Izquierdo JA; Pedraz JL
    Chemotherapy; 2007; 53(3):194-201. PubMed ID: 17356270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of antifungal agent micafungin in critically ill patients receiving continuous hemodialysis filtration.
    Hirata K; Aoyama T; Matsumoto Y; Ogawa F; Yamazaki H; Kikuti A; Yamamoto Y
    Yakugaku Zasshi; 2007 May; 127(5):897-901. PubMed ID: 17473532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin.
    van den Anker JN; Hop WC; Schoemaker RC; van der Heijden BJ; Neijens HJ; de Groot R
    Br J Clin Pharmacol; 1995 Nov; 40(5):439-43. PubMed ID: 8703647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics and dosing simulations of ceftazidime in critically ill patients receiving sustained low-efficiency dialysis.
    König C; Braune S; Roberts JA; Nierhaus A; Steinmetz OM; Baehr M; Frey OR; Langebrake C; Kluge S
    J Antimicrob Chemother; 2017 May; 72(5):1433-1440. PubMed ID: 28175308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of ceftazidime in febrile neutropenic patients.
    Nyhlén A; Ljungberg B; Nilsson-Ehle I
    Scand J Infect Dis; 2001; 33(3):222-6. PubMed ID: 11303815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporary interruption of ceftazidime continuous infusion without reduction of activity: a computer-assisted simulation.
    Castagnola E; Ros L
    J Chemother; 2001 Aug; 13(4):395-401. PubMed ID: 11589482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine removal by plasma exchange with continuous hemodiafiltration in critically ill patients.
    Nakae H; Asanuma Y; Tajimi K
    Ther Apher; 2002 Dec; 6(6):419-24. PubMed ID: 12460404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration.
    Yagasaki K; Gando S; Matsuda N; Kameue T; Ishitani T; Hirano T; Iseki K
    Intensive Care Med; 2003 Oct; 29(10):1844-8. PubMed ID: 13680113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, intramuscular bioavailability and tissue residue profiles of ceftazidime in a rabbit model.
    Abd El-Aty AM; Goudah A; Abo El Sooud K
    Dtsch Tierarztl Wochenschr; 2001 Apr; 108(4):168-71. PubMed ID: 11370478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.